Menu
Curie Logo
Donate
  • Home

Clinical trials - page 2

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Saint-Cloud
    START
    A Randomized Phase 2 Study in Patients With Triple-negative Androgen Receptor Positive Locally Recurrent (Unresectable) or Metastatic Breast Cancer Treated With Darolutamide or Capecitabine

    FLORENCE LEREBOURS

  • Saint-Cloud
    STERIMGLI
    A Phase I/II Multicenter Trial Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and the Anti-Programmed Death-ligand 1 (PD-L1) Durvalumab (Medi4736) for Patients With Recurrent Glioblastoma (STERIMGLI).

  • Sarcomas
    Paris
    STRASS 2 - ETUDE 1809-STBSG
    A randomized phase III study of neoadjuvant chemotherapy;followed by surgery versus surgery alone for patients with;High Risk RetroPeritoneal Sarcoma (STRASS 2)

    SYLVIE BONVALOT

  • Saint-Cloud
    SUMMIT- PUMA-NER-0502
    An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.

    FRANCOIS-CLEMENT BIDARD

  • Lung cancer
    Paris
    TAS6417-201
    An Open-Label, Phase 2b, Global Multicenter Cohort Trial to;Assess the Safety and Efficacy of Zipalertinib in Patients;with Locally Advanced or Metastatic Non-Small Cell Lung;Cancer with Exon 20 Insertion and Uncommon/Single or;Compound Epidermal Growth Factor Receptor Mutations.

    NICOLAS GIRARD

  • Lung cancer
    Paris
    TAS6417-301
    Randomized, Controlled, Open-label, Phase 3, Global Multi-;Center Trial to Assess the Efficacy and Safety of Zipalertinib;plus Chemotherapy versus Chemotherapy alone, in Patients;with Previously Untreated, Locally Advanced or Metastatic;Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with;Epidermal Growth Factor Receptor (EGFR) Exon 20;Insertion (ex20ins) Mutations.

    NICOLAS GIRARD

  • Saint-Cloud
    TEDOPaM Prodige 63
    A randomized non-comparative phase II study of Maintenance therapy with OSE2101 plus FOLFIRI, or FOLFIRI after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic Pancreatic ductal adenocarcinoma (TEDOPaM - D17-01 PRODIGE 63 Study).

  • Prostate cancer
    Paris, Saint-Cloud
    TEMPOS (GETUG P14)
    Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy

    GILLES CREHANGE

  • ENT/Head and Neck Cancers
    Paris
    TG4050.02
    A randomized phase I trial in patients with newly-diagnosed, locoregionally advanced, HPV-negative, squamous cell carcinoma of the head and neck (SCCHN);evaluating a mutanome-directed immunotherapy;initiated at completion of primary treatment or at time of recurrence

    EDITH BORCOMAN

  • Breast cancer
    Paris
    TRANS ROSALEE
    A BIOMARKER-DIRECTED, TRANSLATIONAL STUDY OF HIGH-THROUGHPUT MOLECULAR PROFILING OF HR+/HER2- METASTATIC BREAST CANCER TREATED WITH ENDOCRINE THERAPY AND RIBOCICLIB.

    HELENE SALAUN

  • Paris, Saint-Cloud
    TUMOSPEC (ONCO04) - Paris
    Investigation of Tumour Spectrum, Penetrance and Clinical Utility of Germline Mutations in New Breast and Ovarian Cancer Susceptibility Genes.

    DOMINIQUE STOPPA-LYONNET

  • Lung cancer
    Paris
    Telimet-01: M18-868
    A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin;(ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype,;Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.

    NICOLAS GIRARD

  • Saint-Cloud
    YO39523
    A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  • Childhood and adolescent cancers
    Paris
    eSMART
    European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors.

    ISABELLE AERTS GAJDOS

  • Childhood and adolescent cancers
    Paris
    iMATRIX-Alectinib (GO42286)
    A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available.

    FRANCOIS DOZ

  • ENT/Head and Neck Cancers
    Paris
    219885 GALAXIES H&N-202
    A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

    CHRISTOPHE LE TOURNEAU

  • Colorectal cancer
    Saint-Cloud
    ADAGE - Prodige 34
    Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over.

  • Sarcomas
    Paris
    ADCT-601-102
    A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to;Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor;Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in;Combination with Other Anti-Cancer Therapies in Patients with Selected;Advanced Solid Tumors.

  • Saint-Cloud
    AIPAC
    AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel

    ETIENNE BRAIN

  • Lung cancer
    Paris
    AK112-301-HARMONi
    A randomized, double-blind, multi-center, Phase III Study of AK112 or placebo combined with;pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic nonsquamous;NSCLC who have failed to EGFR-TKI treatment.

    NICOLAS GIRARD

  • Breast cancer
    Paris, Saint-Cloud
    ALCINA-2
    Analysis of Circulating Tumor Markers in Blood

    FRANCOIS-CLEMENT BIDARD

  • Breast cancer
    Paris, Saint-Cloud
    ALCINA-4 (IC 2020-11)
    Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4

    FRANCOIS-CLEMENT BIDARD

  • Paris, Saint-Cloud
    ALCYTA (IC 2020-12)
    Exploration of Adaptive Antitumoral Immune Cells Through Leukapheresis in Cancer Patients: ALCYTA

    NICOLAS GIRARD

  • Saint-Cloud
    ALPHABET
    Randomized phase III trial of the administration of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with a PIK3CA mutation and previously treated for advanced HER2+ cancer

    FRANCOIS-CLEMENT BIDARD

  • Saint-Cloud
    AMEBICA - Prodige 38
    Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours.

  • Saint-Cloud
    AML LI-1
    A PROGRAMME OF DEVELOPMENT FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME

    JACQUES VARGAFTIG

  • Saint-Cloud
    APACaP
    Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

  • Saint-Cloud
    AcSé Pembrolizumab
    Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types.

    CAROLE SOUSSAIN

  • Saint-Cloud
    AcSé Vemurafenib
    Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

    ETIENNE BRAIN

  • Sarcomas
    Paris
    BFR ESS 01
    Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS

    SOPHIE PIPERNO-NEUMANN

<
1 2...7
>